EP1620464A1 - Utilisation combinee d'agonistes de facteur de croissance de keratinocytes et de composes de gastrine - Google Patents

Utilisation combinee d'agonistes de facteur de croissance de keratinocytes et de composes de gastrine

Info

Publication number
EP1620464A1
EP1620464A1 EP04730429A EP04730429A EP1620464A1 EP 1620464 A1 EP1620464 A1 EP 1620464A1 EP 04730429 A EP04730429 A EP 04730429A EP 04730429 A EP04730429 A EP 04730429A EP 1620464 A1 EP1620464 A1 EP 1620464A1
Authority
EP
European Patent Office
Prior art keywords
kgf
gastrin
agonist
cells
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04730429A
Other languages
German (de)
English (en)
Inventor
Stephen J Brand
Antonio Cruz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Waratah Pharmaceuticals Inc
Original Assignee
Waratah Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waratah Pharmaceuticals Inc filed Critical Waratah Pharmaceuticals Inc
Publication of EP1620464A1 publication Critical patent/EP1620464A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes

Definitions

  • the invention relates generally to compositions, conjugates, and methods comprising a keratinocyte growth factor agonist and a gastrin compound, and uses thereof.
  • the fibroblast growth factor (FGF) family consists of at least 22 structurally related polypeptides (named FGF-1 to FGF-22).
  • the members of the FGF family typically range in molecular mass from 17 to 34 kDa and share 13-71% amino acid identity.
  • FGFs are highly conserved in both gene structure and amino- acid sequence among vertebrate species.
  • the various FGF molecules exhibit a broad range of biological activities in normal and malignant conditions. These activities include angiogenesis, mitogenesis, cellular differentiation, and wound repair (Baird, A. et al, Cancer Cells 3:239-243 (1991); Burgess, W. H. et al., Annu. Rev. Biochem. 58:575-606 (1989)).
  • FGFs consists of at least 22 structurally related polypeptides (named FGF-1 to FGF-22).
  • the members of the FGF family typically range in molecular mass from 17 to 34 kDa and share 13-71% amino acid identity.
  • Keratinocyte growth factor (KGF, KGF-1, or FGF-7) is a member of the FGF family but unlike other members of the FGF family it has little activity on mesenchyme-derived cells but stimulates epithelial cells.
  • KGF has been reported to produce changes in hair, follicle morphogenesis, hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine (Panos et al J. Clin. Invest 92:969-977 (1993); Ulich et al., Am J. Path 144:862-868 1994; Yi et al, Am J Path 145:80-85, 1994; and Ulich et al., J.
  • Keratinocyte growth factor 2 (KGF-2, FGF-10) is a 208 amino acid glycoprotein that has a high protein sequence similarity to FGF-7, and they are both mitogenic for keratinocytes (Em ⁇ to et al, J. Biol. Chem. 272 23191-23194). (See Powers C.J. et al, Endocrine-Related Cancer 7:165-197, 2000 for areview of fibroblast growth factors).
  • KGF administered systemically has been reported to give partial reduction of elevated blood glucose in streptozotocin induced diabetic rats, however, this effect is confined to KGF administered within 1-2 days of the streptozotocin (STZ) (U.S. Patent Number 5,858,977, issued Jan. 12, 1999).
  • STZ streptozotocin
  • the amelioration of diabetes may result from KGF protecting ⁇ cells from the toxicity of streptozotocin.
  • this method may have limited utility, as the loss of ⁇ cells for most diabetics has occurred long before initiation of treatment.
  • KGF was effective in reducing blood glucose only in moderately diabetic rats.
  • KGF administration resulted in long term reduction in blood glucose only if non-fasting blood glucose was below 15mM.
  • the present invention is directed to a combination of a keratinocyte growth factor (KGF) agonist and a gastrin compound that provides beneficial effects in the treatment of conditions for which either a KGF agonist or a gastrin compound have been demonstrated to have a therapeutic effect, including but not limited to diabetes, hypertension, chronic heart failure, fluid retentive states, metabolic syndrome and related diseases and disorders, and obesity.
  • KGF keratinocyte growth factor
  • gastrin compound that provides beneficial effects in the treatment of conditions for which either a KGF agonist or a gastrin compound have been demonstrated to have a therapeutic effect, including but not limited to diabetes, hypertension, chronic heart failure, fluid retentive states, metabolic syndrome and related diseases and disorders, and obesity.
  • Combinations of a KGF agonist and a gastrin compound may be selected to provide unexpectedly additive effects or greater than additive effects i.e. synergistic effects.
  • a composition, conjugate, or combination therapy comprising a KGF agonist and a gastrin compound employing different mechanisms to achieve maximum therapeutic efficacy, may improve tolerance to the therapy with a reduced risk of side effects that may result from higher doses or longer term monotherapies (i.e. therapies with each compound alone).
  • a composition or combination treatment of the invention can permit the use of lower doses of each compound with reduced adverse toxic effects of each compound.
  • a suboptimal dosage may provide an increased margin of safety, and may also reduce the cost of a drug necessary to achieve prophylaxis and therapy.
  • a treatment utilizing a single combination dosage unit will provide increased convenience and may result in enhanced compliance.
  • the invention contemplates a composition, preferably a pharmaceutical composition, comprising a KGF agonist and a gastrin compound.
  • a pharmaceutical composition may optionally comprise a pharmaceutically acceptable carrier, excipient, or vehicle. .
  • the composition provides beneficial effects relative to each compound alone.
  • the invention contemplates a pharmaceutical composition comprising a KGF agonist and a gastrin compound which provides beneficial effects, preferably sustained beneficial effects, following treatment.
  • the beneficial effects provided by a composition of the invention can include increased absorption, distribution, metabolism and/or elimination of KGF agonist and/or gastrin compound.
  • a composition can have increased bioavailability (absorbed more rapidly and to a higher degree) or provide enhanced therapeutic effects.
  • the invention also provides a pharmaceutical composition for the treatment of a disease or condition comprising a therapeutically effective amount of a KGF agonist and a gastrin compound in a pharmaceutically acceptable carrier, excipient, or vehicle.
  • the invention features a composition comprising a gastrin compound and a KGF agonist.
  • the composition is in a dosage effective for inducing proliferation of islet precursor cells into an increased amount of mature insulin secreting cells. Further, the composition is in a dosage effective for inducing differentiation of an islet precursor cell into a mature insulin secreting cell.
  • the composition can be in a pharmaceutically acceptable carrier.
  • the invention provides a conjugate comprising a KGF agonist linked to a gastrin compound.
  • a conjugate can provide the beneficial effects described herein.
  • the invention also provides methods for preparing compositions and conjugates of the invention that result in compositions and conjugates with beneficial effects.
  • the invention provides a method of preparing a stable pharmaceutical composition of a KGF agonist adapted to provide beneficial effects following treatment, comprising preparing a composition comprising the KGF agonist, a gastrin compound, and a pharmaceutically acceptable carrier, excipient, or vehicle effective to physically stabilize the KGF agonist -and/or gastrin compound.
  • the invention also contemplates the use of a composition or conjugate of the invention or combination treatment of the invention for preventing, and/or ameliorating disease severity, disease symptoms, and/or periodicity of recurrence of a disease or condition described herein.
  • the invention also relates to the prevention and treatment, in a subject, of conditions or diseases using the compositions, combination treatments, and conjugates of the invention.
  • the invention provides a method for treating and/or preventing a condition or disease in a subject comprising administering to the subject a therapeutically effective amount of at least one KGF agonist and at least one gastrin compound to provide beneficial effects.
  • the invention provides a treatment method which provides sustained beneficial effects following treatment.
  • the invention provides a method of treating a condition or disease comprising administering a KGF agonist and a gastrin compound, a composition, or conjugate of the invention, with a plurality of cells, to a subject in need thereof to thereby produce beneficial effects.
  • the compounds/composition/conjugate are administered systemically.
  • the invention provides a method for expanding and differentiating stem cells or progenitor cells into insulin secreting cells comprising contacting the stem cells or progenitor cells with a KGF agonist and a gastrin compound, or a composition or conjugate of the invention in sufficient amounts to expand and differentiate stem cells or progenitor cells.
  • the amount of expansion and differentiation may be significantly different compared with that achieved in the absence of the compounds, composition or conjugate.
  • the stem cells or progenitor cells are contacted with the compounds, composition, or conjugate in culture.
  • the stem cells or progenitor cells are contacted with the compounds, composition, or conjugate in a subject.
  • the compounds, composition or conjugate may be administered to a subject before, during, or after implantation of stem cells in the subject to expand and differentiate the stem cells in the subject.
  • the invention also relates to a method for enhancing proliferation of insulin secreting cells in culture comprising contacting the cells 'with a KGF agonist and a gastrin compound, or a composition or conjugate of the invention, in sufficient amounts to enhance proliferation of the cells.
  • the amount of proliferation may be significantly different compared with that achieved in the absence of the compounds, composition or conjugate.
  • the invention also relates to a method for sustaining islet cells or precursor cells in culture comprising culturing the cells in the presence of a KGF agonist and a gastrin compound or a composition or conjugate of the invention in an amount sufficient to sustain the cells in culture.
  • the cells may be sustained in culture for a significantly longer period of time compared with cells cultured in the absence of the compounds, composition or conjugate. Culturing cells in the presence of a KGF agonist and a gastrin compound or a composition or conjugate of the invention will be particularly useful in preparing and maintaining cells intended for transplantation.
  • the invention further relates to a method for treating a subject with a condition or disease described herein comprising contacting ex vivo a plurality of cells with a KGF agonist and a gastrin compound, or a composition or conjugate of the invention, optionally culturing the cells, and administering the cells to the subject in need thereof.
  • the invention still further relates to inducing islet neogenesis in a subject comprising contacting islet precursor cells with a KGF agonist and a gastrin compound, composition, or conjugate of the invention in a sufficient amount to increase proliferation of islet precursor cells in the subject thereby inducing islet neogenesis.
  • the invention provides methods for treating diabetes mellitus in a patient in need thereof by administering a composition comprising a gastrin compound and a KGF agonist in an amount sufficient to effect differentiation of the patient's pancreatic islet precursor cells to mature insulin-secreting cells and/or to stimulate insulin synthesis in existing islet cells.
  • the composition can be administered systemically or expressed in situ by host cells containing a nucleic acid construct in an expression vector wherein the nucleic acid construct comprises a coding sequence for a gastrin compound and or a coding sequence for a KGF agonist, together with transcriptional and translational regulatory regions functional in pancreatic islet precursor cells.
  • pancreatic islet cells that have been exposed in culture to a sufficient amount of a gastrin compound and a KGF agonist to increase the number of pancreatic beta cells in the islets; optionally the population of pancreatic beta cells can be grown in culture for a time sufficient to expand the population of ⁇ -cells prior to transplantation.
  • composition comprising a combination of at least one
  • the invention relates to the use of synergistically effective amounts of at least one KGF agonist, and at least one gastrin compound for the preparation of a medicament for preventing and/or treating a condition or disease.
  • the invention additionally provides uses of a pharmaceutical composition and a conjugate of the invention in the preparation of medicaments for the prevention and/or treatment of conditions and diseases.
  • the medicaments provide beneficial effects, preferably sustained beneficial effects following treatment.
  • the invention in an embodiment provides a method for preventing and/or treating diabetes, the method comprising administering to a mammal in need thereof a composition comprising a combination of a
  • KGFR ligand such as KGF or FGF-7 or KGF-2 or FGF-10 and a gastrin compound (e.g. gastrin /CCK receptor ligand), in an amount sufficient to increase the number of pancreatic insulin secreting ⁇ cells in the mammal, thereby preventing and/or treating the diabetes.
  • the composition is administered systemically.
  • the mammal is a diabetic mammal, for example, the mammal has been diabetic for an extent of 1% of the lifespan of the mammal.
  • the amount of KGF agonist in the composition can be substantially lower than the minimum effective dose of KGF agonist required to reduce blood glucose in the diabetic mammal in the absence of a gastrin compound.
  • the KGF agonist and the gastrin compound are provided in an amount sufficient to induce differentiation of the pancreatic islet precursor cells into glucose responsive insulin secreting islet cells.
  • Another embodiment of the invention provides a method-for preventing and/or treating diabetes, the method comprising administering to a mammal in need thereof a composition comprising a combination of a KGF agonist and a gastrin compound (e.g. gastrin /CCK receptor ligand), in an amount sufficient to increase , proliferation of islet precursor cells in pancreatic tissue, thereby preventing and/or treating the diabetes.
  • a gastrin compound e.g. gastrin /CCK receptor ligand
  • the methods of the invention can further comprise administering at least one agent for suppression of immune response, for example, the agent is selected from rapamycin cyclosporin, ISAtx247 and FK506.
  • the agent is selected from rapamycin cyclosporin, ISAtx247 and FK506.
  • Another embodiment of the invention provides a method for preventing and/or treating diabetes, the method comprising: contacting ex vivo a plurality of cells with a composition comprising a KGF agonist and a gastrin compound (e.g. gastrin /CCK receptor ligand) in an amount sufficient to increase proliferation of islet precursor cells and the amount of insulin secreting islet cells; and administering the contacted plurality of cells to a mammal in need thereof, thereby preventing and/or treating the diabetes.
  • the cells can be autologous.
  • the composition is provided in an amount sufficient to effect differentiation of stem cells, for example, to effect differentiation of pancreatic islet precursor cells in pancreatic tissue into mature insulin secreting islet cells.
  • the composition is provided in an amount sufficient to increase proliferation of pancreatic islet stem cells, for example, of pancreatic islet precursor cells.
  • Stem cells can be obtained either from a pancreatic tissue or from a non-pancreatic tissue, such as liver or bone marrow.
  • an embodiment of the invention provides a method for expanding and differentiating stem cells in a diabetic recipient of the cells into insulin secreting cells, the method comprising implanting the cells in the recipient, and administering a composition containing an effective dose of each of a gastrin compound and a KGF agonist.
  • the implanted cells are obtained from a human, for example, are obtained from human pancreatic islets, human liver, human bone marrow, human umbilical cord, or human embryos. Implanting the cells into the recipient may be by a route such as injecting directly into an organ, for example, into the pancreas, the kidney, or the liver.
  • implanting the cells may be administering by intravenous injection, for example, into the portal vein or into the hepatic vein.
  • prior to implanting the cells are treated ex vivo with a composition comprising a gastrin compound and a KGF agonist.
  • the invention provides a method for preventing and/or treating diabetes, the method comprising administering to a mammal in need thereof a composition comprising a combination of a KGF agonist and a gastrin compound (e.g gastrin /CCK receptor ligand), in an amount sufficient to increase the number of pancreatic insulin secreting ⁇ cells in the mammal; and determining the amount of islet neogenesis, thereby preventing and or treating the diabetes. Determining the amount of islet neogenesis is measured by a parameter selected from the group of: blood glucose, serum glucose, blood glycosylated hemoglobin, pancreatic, ⁇ cell mass, serum insulin, and pancreatic insulin content.
  • a parameter selected from the group of: blood glucose, serum glucose, blood glycosylated hemoglobin, pancreatic, ⁇ cell mass, serum insulin, and pancreatic insulin content.
  • Administering the composition reduces blood glucose compared to blood glucose assayed prior to administering the composition.
  • Glycosylated hemoglobin concentration is reduced compared to glycosylated hemoglobin concentration in the mammal assayed prior to administering the composition.
  • Serum insulin concentration is increased compared to serum insulin concentration in the mammal assayed prior to administering the composition.
  • Pancreatic insulin concentration is increased compared to pancreatic insulin concentration in the mammal assayed prior to administering the composition.
  • the invention provides a method for inducing pancreatic islet neogenesis in a mammal, the method comprising administering to the mammal a composition comprising a combination of a KGF agonist and a gastrin compound, in an amount sufficient to increase proliferation of islet precursor cells . in pancreatic tissue, thereby inducing pancreatic islet neogenesis.
  • the plurality of cells can be multicellular. The plurality of cells are delivered systemically to the mammal.
  • the invention provides a method for inducing pancreatic islet neogenesis in a mammal, the method comprising administering a composition comprising a combination of a KGF agonist and a gastrin compound, in an amount sufficient to increase the number of pancreatic insulin secreting ⁇ cells in the mammal.
  • the invention provides a method for inducing islet neogenesis therapy in a cell of an animal, comprising contacting the cell with a nucleic acid sequence encoding a gastrin compound operably linked to a regulatory element, for example, an insulin promoter receptor ligand and a nucleic acid sequence encoding a KGF agonist operably linked to a regulatory element, for example, a metallothionein promoter.
  • a regulatory element for example, an insulin promoter receptor ligand
  • a nucleic acid sequence encoding a KGF agonist operably linked to a regulatory element for example, a metallothionein promoter.
  • the cell is a germ cell, or the cell is an autologous cell cultured ex vivo.
  • the invention provides a nucleic acid construct comprising a nucleic acid sequence encoding a mammalian KGF agonist operably linked to a heterologous promoter and a nucleic acid sequence encoding a mammalian gastrin compound operably linked to a heterologous promoter.
  • the invention provides a transgenic animal whose germ cells comprise a nucleic acid sequence encoding a mammalian KGF agonist operably linked to a heterologous promoter and a nucleic acid sequence encoding a mammalian gastrin compound operably linked to a heterologous promoter.
  • the present invention relates to a method of treatment comprising a combination of active agents which may be administered separately or as conjugates or compositions
  • the invention also provides a kit comprising a KGF agonist and a gastrin compound, a pharmaceutical composition, or conjugate of the invention in kit form.
  • the invention provides a kit for preventing and/or treating diabetes, containing a composition comprising a gastrin compound and a KGF agonist, a container, and instructions for use.
  • the composition of the kit can further comprise a pharmaceutically acceptable carrier.
  • Figure 1 is a graph showing fasting blood glucose levels in vehicle-treated mice and in mice treated with a combination of a KGF and a gastrin.
  • subject refers to an animal including a warm-
  • Mammal includes without limitation any members of the Mammalia.
  • the terms refer to a human.
  • the terms also include domestic animals bred for food or as pets, including horses, cows, sheep, poultry, fish, pigs, cats, dogs, and zoo animals, rats, goats, apes (e.g. gorilla or chimpanzee), and rodents such as rats and mice.
  • the methods herein for use on subjects/individuals/patients contemplate prophylactic as well as curative use.
  • Typical subjects for treatment include persons susceptible to, suffering from or that have suffered a condition or disease described herein.
  • a subject may be non-diabetic, pre-diabetic, or diabetic.
  • pharmaceutically acceptable carrier refers to a medium which does not interfere with the effectiveness or activity of an active ingredient and which is not toxic to the hosts to which it is administered.
  • a carrier, excipient, vehicle, or diluent includes binders, adhesives, lubricants, disintegrates, bulking agents, wetting or emulsifying agents, pH buffering agents, and miscellaneous materials such as absorbants that may be needed in order to prepare a particular composition.
  • carriers etc include but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The use of such media and agents for an active substance is well known in the art.
  • “Pharmaceutically acceptable salt(s),” includes salts of acidic or basic groups which may be present in the compounds suitable for use in the present invention.
  • Examples of pharmaceutically acceptable salts include sodium, calcium, ammonium, ferric hydroxides, isopropylamine, triethylamine, 2-ehylamine, 2- ethylamino, ethanol, histidine, procarine, and potassium salts of carboxylic acid groups and hydrochloride salts of amino groups.
  • salts of amino groups are hydrobromide, sulfate, hydrogen sulfate, phosphate, acetate, oxalic, hydrogen phosphate, dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts.
  • preventing and/or treating refers to the administration to a subject of a composition or conjugate of the invention either before or after onset of a condition or disease.
  • a treatment may be either performed in an acute or chronic way.
  • a “beneficial effect” refers to an effect of a combination of a KGF agonist and a gastrin compound, or composition or conjugate thereof, in particular an effect that is greater than the effect of either of the compounds alone.
  • the beneficial effect includes favorable pharmacological and/or therapeutic effects, and improved pharmacokinetic properties and biological activity.
  • a beneficial effect may be an additive effect or synergistic effect.
  • beneficial effects include but are not limited to the following: reduced or absent islet inflammation, decreased or prevention of disease progression, increased survival, or treat or reverse a disease or condition.
  • the beneficial effects can be evidenced in diabetes by one or more of the following: (a) a reduction in fasting blood glucose levels, in particular when blood glucose levels are greater than 7-10 mM; (b) reduction in glycosylated haemoglobin; (c) increase in serum insulin concentration; (d) an increase in pancreatic insulin production or content; and/or (e) prevention of disease progression.
  • the beneficial effects comprise (a), b) and (c), or (a), (c), and (d).
  • the beneficial effect is a "sustained beneficial effect" where the beneficial effect is sustained for a prolonged period of time after termination of treatment.
  • a beneficial effect may be sustained for at least about 2 to 4 weeks, 2 to 8 weeks, 2 to 12 weeks, 2 to 24 weeks, 2 weeks to 12 months, and 2 weeks to 18 months following treatment.
  • the period of time a beneficial effect is sustained may correlate with the duration and timing of the treatment.
  • a subject may be treated continuously for about 2 to 8 weeks, 2 to 12 weeks, 2 to 16 weeks, 2 weeks to 6 months, 2 weeks to 12 months, or periodically.
  • a sustained beneficial effect may manifest as one or more of increased C-peptide production, increased pancreatic insulin production or concentration, and about normal or low blood glucose levels for a prolonged period following treatment.
  • the beneficial effect may be a statistically significant effect in terms of statistical analysis of an effect of the two compounds versus the effects of each of the compounds. "Statistically significant" or
  • “significantly different” effects or levels with two compounds compared with each compound alone may represent levels that are higher or lower than a standard. In embodiments of the invention, the difference may be 1.5, 2, 3, 4, 5, or 6 times higher or lower compared with the effect obtained with each compound alone.
  • additive effect of a KGF agonist and a gastrin compound refers to an effect that is equal to the sum of the effects of the two individual compounds
  • a “synergistic effect" of a KGF agonist and a gastrin compound refers to an effect that is greater than the additive effect which results from the sum of the effects of the two individual compounds.
  • a “combination treatment” or “administering in combination” means that the active ingredients are administered concurrently to a patient being treated. When administered in combination each component may be administered at the same time, or sequentially in any order at different points in time. Therefore, each component may be administered separately, but sufficiently close in time to provide the desired effect, in particular a beneficial, additive, or synergistic effect.
  • the first compound may be administered in a regimen which additionally comprises treatment with the second compound.
  • “Therapeutically effective amount” relates to the amount or dose of active compounds (e.g. KGF agonist and gastrin compound) or compositions or conjugates of the invention that will lead to one or more desired beneficial effects, in particular, one or more sustained beneficial effects.
  • a therapeutically effective amount of a substance may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the substance to elicit a desired response in the individual. Dosage procedures may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may ' be proportionally reduced as indicated by the exigencies of the therapeutic situation.
  • Suboptimal dose or suboptimal dosage refers to a dose or dosage of an active compound which is less than the optimal dose or dosage for that compound when used in monotherapy.
  • a “native-sequence polypeptide” or " a native polypeptide” comprises a polypeptide having the same amino acid sequence of a polypeptide derived from nature. Such native-sequence polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term specifically encompasses naturally occurring truncated or secreted forms of a polypeptide, polypeptide variants including naturally occurring variant forms (e.g. alternatively spliced forms or splice variants), and naturally occurring allelic variants.
  • polypeptide variant means a polypeptide having at least about 70-80%, preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95% amino acid sequence identity with a native-sequence polypeptide, in particular having at least 70-80%, 85%, 90%, 95%, 98%, or 99% amino acid sequence identity to the sequences identified in any of SEQ ID NOs. 1 through 11.
  • Such variants include, for example, polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the full-length or mature sequences of SEQ ID NOs: 1 through 11 including variants from other species, but excludes a native-sequence polypeptide.
  • Percent identity of two amino acid sequences, or of two nucleic acid sequences identified herein is defined as the percentage of amino acid residues or nucleotides in a candidate sequence that are identical with the amino acid residues in a polypeptide or nucleic acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent' amino acid or nucleic acid sequence identity can be achieved in various conventional ways, for instance, using publicly available computer software including the GCG program package (Devereux J. et al., Nucleic
  • Skilled artisans can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal • alignment over the full length of the sequences being compared.
  • an “analog” refers to a polypeptide wherein one or more amino acid residues of a parent polypeptide have been substituted by another amino acid residue, one or more amino acid residues of a parent polypeptide have been inverted, one or more amino acid residues of the parent polypeptide have been deleted, and/or one or more amino acid residues have been added to the parent peptide. Such an addition, substitution, deletion, and/or inversion may be at either of the N-terminal or C-terminal end or within the parent polypeptide, or a combination thereof.
  • Mutations may be introduced into a polypeptide by standard methods, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative substitutions can be made at one or more predicted non-essential amino acid residues.
  • a "conservative amino acid substitution” is one in which an amino acid residue is replaced with an amino acid residue with a similar side chain.
  • Amino acids with similar side chains are known in the art and include amino acids with basic side chains (e.g. Lys, Arg, His), acidic side chains (e.g. Asp, Glu), uncharged polar side chains (e.g. Gly, Asp, Glu, Ser, Thr, Tyr and Cys), nonpolar side chains (e.g.
  • Mutations can also be introduced randomly along part or all of the native sequence, for example, by saturation mutagenesis. Following mutagenesis the variant polypeptide can be recombinantly expressed.
  • a “derivative” refers to a polypeptide in which one or more of the amino acid residues of a parent polypeptide have been chemically modified.
  • a chemical modification includes adding chemical moieties, creating new bonds, and removing chemical moieties.
  • a polypeptide may be chemically modified, for example, by alkylation, acylation, glycosylation, pegylation, ester formation, deamidation, or amide formation.
  • a "chimeric polypeptide” comprises all or part (preferably biologically active) of a selected polypeptide operably linked to a heterologous polypeptide (i.e., a polypeptide other than the selected polypeptide).
  • a heterologous polypeptide i.e., a polypeptide other than the selected polypeptide.
  • the term "operably linked” is intended to indicate that a selected polypeptide and the heterologous polypeptide are fused in-frame to each other.
  • the heterologous polypeptide can be fused to the N-terminus or C-terminus of a selected polypeptide.
  • Chimeric and fusion proteins can be produced by standard recombinant DNA techniques.
  • keratinocyte growth factor agonist or "KGF agonist” is understood to refer to any compound, including peptides and non-peptide compounds, which fully or partially, directly or indirectly, potentiate, induce, mimic, or otherwise enhance the activity of keratinocyte growth factors or their receptors.
  • a KGF agonist fully or partially activates a human keratinocyte growth factor receptor. Without being limited by any specific mechanism, full or partial activation of a human keratinocyte growth factor receptor may thereby modulate an FGF signaling pathway and thus contribute to a condition or , disease.
  • a keratinocyte growth factor receptor includes receptors that associate with a keratinocyte growth factor, including but not limited to FGFR-2,lllb and/or FGFR-l,lllb.
  • a "keratinocyte growth factor agonist” or “KGF agonist” is any peptide or non-peptide small molecule or compound that associates, binds to, interacts with, or stimulates a KGF receptor ("KGF receptor ligand"), preferably with a selected affinity constant (KD) or a potency (EC 50 ) as measured by methods known in the art.
  • a KGF agonist exhibits insulinotropic activity, where insulinotropic activity may be measured in vivo or in vitro assays known to those of ordinary skill in the art.
  • a KGF agonist stimulates proliferation of keratinocytes.
  • a KGF agonist is selected that stimulates proliferative metaplasia of the pancreatic ducts, including re-activation of ⁇ islet cell neogenesis.
  • a KGF agonist includes native-sequence or synthetic polypeptides, fragments, analogs (e.g. muteins), derivatives, isoforms, chimeric polypeptides, polypeptides with sequence identity, peptidomimetics, and pharmaceutically acceptable salts thereof, and active metabolites and prodrugs.
  • a KGF agonist includes active analogs, ' fragments and other modifications, which for example share amino acid sequence identity with a native-sequence KGF agonist (e.g. KGF or KGF-2), for example, share 60%, 70%, 80%, 90%, 95%, 98%, or 99% sequence identity.
  • a KGF agonist is a KGF receptor ligand, in particular a keratinocyte growth factor or KGF.
  • Keratinocyte 1 growth factors are tyrosine kinase receptor growth factors with biological actions similar to EGF receptor ligands.
  • KGF stimulates via a tyrosine kinase receptor different from EGF receptor, causing increased proliferation of epithelial precursors in many epithelial cell types (Krakowski, M.L. et al., Am. J. Pathol. 154:683-691, 1999). It has a unique target cell specificity. In general,
  • KGF stimulates the proliferation and differentiation of a variety of cell types derived from the primary or secondary mesoderm as well as from neuroectoderm. KGF stimulates epithelial cell proliferation but unlike other FGF's it does not stimulate endothelial cells or fibroblast proliferation (Finch P.W. et al, Science 245:
  • a KGF includes a native-sequence full length polypeptide, excluding the signal sequence, designated KGF ⁇ 63 (KGF or FGF-7) comprising 163 amino acids, and possessing a potential N-glycosylation site at amino acid 14 of the consensus sequence for glycosylation that extends from amino acids 14 to 16 at the N-terminus (Finch P.W. et al, Science 245: 752-755, 1989).
  • fgf-7 codes for a 194 amino acid protein containing a signal sequence (Aaronson SA, Bottaro DP, Miki T, Ron D, Finch PW, Fleming TP, Ahn J, Taylor WG and Rubin JS 1991, Annals of the New York Academy of Sciences 638: 62-77).
  • SEQ ID NOs: 1, 2, and 10 An amino acid sequence for a KGF is shown in SEQ ID NOs: 1, 2, and 10, (SEQ ID NO:. 10 is 163 amino acids and an initiating methionine), and includes interchangeably unless otherwise indicated, native KGF and KGF analogs (e.g. muteins) characterized by a peptide sequence substantially the same as the peptide sequence of native KGF and by retaining some or all of the biologically activity of native KGF, particularly non-fibroblast epithelial cell proliferation (e.g.
  • a KGF also includes the native sequence of KGF-2 (FGF-10) which is a 208 amino acid glycoprotein with a signal sequence ((Emoto et al, 1997, supra; Yamasaki et al., J.Biol. Chem. 271:15918-
  • KGF-2 is shown in SEQ ID NOs: 3, 4, and 11 (SEQ ID NO: 11 is 169 amino acids and an initiating methionine).
  • a KGF agonist for use in the present invention includes a KGF of SEQ ID NO: 1, 2, 3, or 4 without the signal sequence (e.g. about the first 30-40 amino acid residues; see SEQ ID NOs.: 10 or 11).
  • a KGF agonist for use in the present invention is repifermin (Human Genome Sciences, Rockville, MD) or palifermin (Amgen, Thousand Oaks, Cal.).
  • a KGF agonist can be prepared by conventional methods known in the art.
  • an amino acid portion of a KGF agonist can be prepared by a variety of methods known in the art such as solid-phase synthesis, purification of KGF agonists from natural sources, recombinant technology, or a combination of these methods. See for example, United States Patent Nos. WO 90/08771, and, Dugas and Penney 1981, Merrifield, 1962, Stewart and Young 1969, and the references cited herein.
  • a KGF agonist in particular a KGF
  • a KGF can be produced by recombinant methods well known to those skilled in the art.
  • the invention contemplates the use of a nucleotide sequence encoding a KGF agonist, in particular a KGF, and a host cell comprising the nucleotide sequence for the preparation of a KGF agonist.
  • a “gastrin compound” is understood to refer to any compound, including peptides and non-peptide compounds, which fully or partially, directly or indirectly, potentiate, induce, mimic, or otherwise enhance the activity of a gastrin or a gastrin/CCK receptor.
  • a gastrin compound can be used which fully or partially associates and/or activates a gastrin/CCK receptor.
  • a gastrin/CCK receptor includes receptors that associate with a gastrin.
  • a gastrin compound may be a ligand that associates, binds to, interacts with or stimulates a gastrin/CCK receptor, ("gastrin/CCK receptor ligand).
  • a gastrin compound may be selected that is a peptide or non-peptide small molecule that has a suitable IC 5 o, for example an IC 50 of about ⁇ 0.7 nM, as measured by methods known in the art (see Singh et al (1995) J. Biol. Chem. 270:
  • a “gastrin compound” includes native-sequence or synthetic gastrin polypeptides, fragments, analogs (e.g. muteins), derivatives, isoforms, chimeric polypeptides, polypeptides with sequence identity, peptidomimetics, and pharmaceutically acceptable salts thereof, and active metabolites and prodrugs.
  • gastrin such as gastrin 34 (big gastrin), gastrin 17 (little gastrin), and gastrin 8 (mini gastrin), pentagastrin, tetragastrin and fragments, analogs, and derivatives thereof.
  • gastrin compounds examples include the compounds disclosed in U.S. Patent No. 6,288,301.
  • a gastrin compound may be selected that is a peptide or non-peptide agonist or partial agonist of the gastrin receptor such as A71378 (Lin et al., Am. J. Physiol. 258 (4 Pt 1): G648, 1990).
  • a gastrin compound may be a gastrin CCK receptor ligand including but not limited to gastrin compounds described herein, or a cholecystokinin (CCK) such as CCK 58,' CCK 33, CCK 22, CCK 12 and CCK 8; and the like.
  • CCK cholecystokinin
  • a gastrin compound also includes active analogs, fragments and other modifications, which for example share amino acid sequence identity with an endogenous mammalian gastrin or native-sequence gastrin, for example, share 60%, 70%, 80%, 90%, 95%, 98%, or 99% sequence identity.
  • Gastrin compounds also include substances that increase the secretion of endogenous gastrins, cholecystokinins or similarly active peptides from sites of tissue storage.
  • gastrin releasing peptide examples include the gastric releasing peptide, omeprazole which inhibits gastric acid secretion and increases plasma gastrin levels, soya bean trypsin inhibitor which increases CCK stimulation, and gastrin releasing peptide, which stimulates gastrin secretion without binding to gastrin receptors.
  • Gastrins including big gastrin-34 (Bonato et al , 1986, Life Science 39:959) and small gastrin-17 (Bentley et al (1966) Nature 209:583) are shown in SEQ ID NOs. 5-9. Big gastrin-34 is essentially an extension of an amino acid sequence at the N-terminal end of small gastrin-17.
  • Big gastrin is cleaved in vivo to release gastrin-17.
  • Glp at the N-terminal end is pyroglutamate, which is a. naturally cyclized form of glutamate.
  • cysteine or lysine are added to a terminus of gastrin having a pyroglutamate, the pyroglutamate is replaced with a glutamate, or the pyroglutamate is deleted.
  • each of a gastrin 34 and gastrin-17 can be used having a methionine or a leucine at position 15, as shown in SEQ ID NOs: 5-8 herein.
  • a “gastrin compound” includes a modified form of a gastrin.
  • Various gastrins can be modified including but not limited to gastrin 34 (big gastrin), gastrin 17 (little gastrin), and gastrin 8 (mini gastrin), pentagastrin, and tetragastrin. Sequences for gastrins including big gastrin-34 (Bonato et al , 1986, Life
  • Modified gastrin compounds for use in the present invention comprise the modified gastrin compounds described in PCT/CA03/01778, US Serial No. 10/719,450 and U.S. Application Serial No. 60/519,933 incorporated in their entirety by reference.
  • a modified gastrin compound can have an extended activity upon administration to a subject in comparison to a native- sequence gastrin. They may have a longer half- life in the circulation of a subject.
  • a modified gastrin compound can contain a minimal gastrin component which comprises at least amino acids at positions 29-34 of SEQ ID NO:5 or at positions 12-17 of SEQ ID NO:6. These are located at the carboxy terminus of gastrins that occur in circulation, and in various gastrin compounds contemplated herein additional amino acids, for example from gastrin, can be present.
  • a group of modified gastrin compounds include compounds having an amino acid sequence comprising from the amino terminus Z-Y m -X n -AA 1 -AA 2 -AA 3 -AA 4 -AA 5 -AA fi , wherein AAi is Tyr or Phe,
  • AA 2 is Gly, Ala, or Ser
  • AA 3 is Trp, Val, or He
  • AA 4 is Met or Leu
  • AA 5 is Asp or Glu
  • AA 6 is Phe or
  • Tyr which can be amidated;
  • Z is the sequence of a polymer or a protein (e.g. a serum protein such as human serum albumin);
  • Y m is an optional spacer region comprising m amino acid residues of a small neutral amino acid including but not limited to serine, glycine, and/or alanine, and
  • X is any consecutive portion of residues
  • Y m can be an amino acid sequence comprising m residues having glycine alternating with alanine, for example, [Gly-Ala] 5 or having random sequence of glycine and alanine.
  • the gastrin compound further can have a cysteine residue at the amino terminus of Y, when m is greater than 1, or at the amino terminus of
  • the gastrin compound can further comprise a bifunctional crosslinking agent for linkage to
  • m is 0 to about 20 residues.
  • m is 0, and the compound is X n -AA r AA 2 -AA 3 -AA -AA 5 -AA 6 further comprising a bifunctional cross-linking agent for linkage to Z.
  • the X in certain embodiments is selected from the group of sequences: position 1 to position 11 of SEQ ID NO: 5; position 1 to position 11 of SEQ ID NO: 6; position 2 to position 11 of SEQ ID NO: 7; and position 2 to position 11 of SEQ ID NO: 8.
  • the gastrin compound in which Z is a protein can be recombinantly produced.
  • X is one or more amino acid residues from position 18 to position 28 of
  • the gastrin compounds by virtue of the presence of X, can have any of gastrin sequences from positions 18-28, 19-28, 20-28, 21-28, etc.
  • the gastrin compound optionally contains an amino acid spacer of length m, and m is 0 to about 20 residues.
  • a modified gastrin compound of the formula X n -AA ⁇ -AA 2 -AA 3 -AA 4 -AA 5 -AA s where there is no spacer and m is 0, may further comprise a bifunctional cross-linking agent for linkage to Z, where Z further comprises a non-proteinaceous polymer.
  • the gastrin component contains at least amino acid residues 29-34 of SEQ ID NO: 5 or 6, and it is associated with a polymer, a lipid or a carbohydrate.
  • a polymer may be a synthetic or naturally occurring polymer.
  • the term polymer includes a protein polymer of amino acids, and is not limited to a synthetic polymer.
  • the polymer may be a polyethylene glycol (PEG) or a dextran.
  • PEG polyethylene glycol
  • the polymer is a protein, in various embodiments it can be a serum protein, for example, a serum albumin, for example, human serum albumin.
  • a modified gastrin compound can be based on SEQ ID NO: 5 or 6 or "big" gastrin-34 and have a residue at position 32 which is a methionine or a leucine, respectively. .
  • Another preferred modified gastrin compound comprises a structure Z-Y m -X, wherein Z is Cys or Lys, Y m is an optional spacer region comprising m amino acid residues of a small neutral amino acid, and X is at least six amino acid residues comprising at least positions 12-17 of gastrin-17 (SEQ ID NO: 7 or 8) or at least positions 29-34 of gastrin-34 (SEQ ID NO: 5 or 6).
  • This modified gastrin compound can further comprise a bifunctional cross-linking agent wherein one reactive portion of the cross-linking agent is covalently linked to Z, and the other reactive portion is covalently linked to a polymer or protein.
  • a modified gastrin can be a gastrin derivative or analog comprising a minimal sequence of 6 amino acids (from the C-terminal end), and further having addition of a reactive group capable of undergoing an addition reaction.
  • a modified gastrin compound may further comprise at least one reactive amino acid such as a cysteine or lysine residue.
  • the reactive amino acid may be added or substituted at the N-terminal end.
  • the addition of the reactive amino acid can be at a, terminal region and a spacer region can optionally precede the added reactive residue.
  • the spacer can be synthesized biologically as part of, or can be chemically attached to the gastrin amino acid sequence, forming a structure which has a gastrin sequence- spacer-cysteine/lysine.
  • the spacer may be a string of several amino acids such as alanine or glycine.
  • a modified gastrin compound AA ⁇ -AA 2 -AA 3 -AA 4 -AA 5 -AA 6 is Tyr-Gly-Trp-
  • a modified gastrin compound can comprise a moiety that is a gastrin compound associated with a larger molecule such as a polymer, either non-covalently, or as a covalent conjugate, or as a fusion protein to another peptidic compound having an amino acid sequence.
  • the modified gastrin compounds can have a longer half-life in circulation in a subject animal or patient, and/or maintain higher concentrations in vivo of the gastrin compounds for an extended period of time compared to the native forms of gastrin.
  • a modified gastrin compound comprises a gastrin compound bound to a comparatively larger structure or a plurality of structures in the blood and still retains the ability to bind target proteins, i.e., a gastrin/CCK receptor.
  • a gastrin compound is attached to a carrier protein which can result in a longer-term of drug efficacy.
  • a gastrin compound can be conjugated to a polymeric carrier such as a polyethylene glycol (PEG) or a dextran to achieve similar objectives
  • chemical modification of a gastrin compound is used to provide compounds that react covalently or non-covalently to carrier proteins or polymeric carriers, either in vitro (ex vivo) or in vivo.
  • the non-covalent interaction is electrostatic or hydrophobic.
  • conjugation of a gastrin compound to the carrier is carried out prior to injection.
  • the gastrin compound is modified in such a manner that when injected, will have an enhanced affinity to the carrier in the bloodstream.
  • long acting gastrin compounds are obtained via chemical modification with no. requirement for a carrier protein either in vivo or ex vivo.
  • the carrier protein is a plasma protein.
  • the plasma protein is an albumin or an immunoglobulin or components of an immunoglobulin.
  • the immunoglobulin or components of the immunoglobulin can be modified or portions deleted prior to conjugation.
  • the polymeric carrier is polyethylene glycol or dextran.
  • activated PEG can be attached to a gastrin compound via an amino group in the gastrin compound (Vernonese, FM. Biomaterials 22(2001)-405-417).
  • the gastrin compound which is a sequence of amino acids is genetically fused with a carrier protein, which is also a sequence of amino acids, prior to injection, using standard recombinant genetic techniques.
  • a gastrin compound can be fused recombinantly to a carrier protein with or without a linker/spacer, for example, comprising a sequence of small neutral uncharged amino acids.
  • a nucleic acid encoding a gastrin compound can be recombinantly fused or synthesized directly as a fusion to portions or the whole of the carrier protein, and the nucleic acid construct or fusion protein can encode or incorporate a number of additional amino acids to, act as a spacer between the two proteins.
  • Recombinant fusion proteins can be expressed in a host cell. Modifications to the sequence of gastrin compound polypeptide can be introduced during construction of the fusion protein if necessary.
  • the gastrin compound is modified to introduce a reactive group such as those present on an amino acid such as a lysine or cysteine so that the reactive group upon further contacting another compound such as a carrier protein or carrier non-proteinaceous polymer, can form covalent interactions with the carrier proteins or polymers.
  • a reactive thiol group can be added to a gastrin compound through an amino group on lysine, for example, using succinimidyl 3-2-pyridyldithio propionate, (SPDP) followed by reduction with DTT to release the active thiol group (("Protein thiolation and reversible protein-protein conjugation. N-SUccinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent.” Carlsson J, Drevin H, Axen R. Biochem J 173, 723-737 (1978)).
  • SPDP succinimidyl 3-2-pyridyldithio propionate
  • the bifunctional group can also be added after the cysteine or lysine has been added, so that one reactive end of the crosslinking agent will react with cysteine/lysine while the other reactive end at the other end is left exposed or is conjugated to a carrier.
  • Thiols can be also incorporated at carboxylic acid groups by EDAC-mediated reaction with cystamine, followed by reduction of the disulfide with DTT. ("Introduction of sulfhydryl groups into proteins at carboxyl sites.” Lin CM, Mihal KA, Krueger RJ. Biochim Biophys Acta 1038, 382-385 (1990).
  • reaction of an amino group on the lysine residue in a gastrin compound with succinimidyl trans-4-(maleimidylmethyl)cyclohexane-l-carboxylate conjuggation of glucose oxidase from Aspergillus niger and rabbit antibodies using N-hydroxysuccinimide ester of N-(4- carboxycyclohexylmethyl)-maleimide.
  • succinimidyl trans-4-(maleimidylmethyl)cyclohexane-l-carboxylate Conjugation of glucose oxidase from Aspergillus niger and rabbit antibodies using N-hydroxysuccinimide ester of N-(4- carboxycyclohexylmethyl)-maleimide.
  • a gastrin compound-carrier complex can include additional modular components including a spacer arm or element or other component that can facilitate preparation or isolation of the gastrin compound- carrier complex or enhance or maintain the functional activity of the gastrin compound.
  • the spacer arm can be one or more amino acids, peptide, a peptidomimetic, or a small organic molecule, and can comprise homobifunctional or heterobifunctional crosslinking agents or chitin oligomers or polyethyelene glycol or related polymers.
  • the carrier and gastrin compound can be covalently crosslinked with or without a spacer arm.
  • non-spacer arms zero-length crosslinkers
  • Homobifunctional crosslinkers that generate a spacer arm can be for instance disuccinimidyl suberate and heterobifunctional crosslinkers that generate a spacer arm can be for instance 2-iminothiolane, succinimidyl 6-[3-(2-pyridyldithio)propionamido] hexanoate (LC-SPDP) and 4-( V-maleimido methyl)cyclohexane-l- carboxylate (SMCC).
  • LC-SPDP succinimidyl 6-[3-(2-pyridyldithio)propionamido] hexanoate
  • SMCC V-maleimido methylcyclohexane-l- carboxylate
  • a gastrin compound is associated with a larger carrier moiety such as a polymer, for example a protein.
  • a carrier moiety such as a polymer, for example a protein.
  • the protein may be considered to be a carrier protein.
  • Classes of carrier proteins can possess the properties of being non- antigenic, i.e., are native human proteins, and are being capable of sustained maintenance in circulation.
  • An ideal carrier protein is one normally found in the human circulatory system.
  • Gastrin compounds may be prepared using conventional processes. For example, small forms of gastrin such as gastrin 17 are economically prepared by peptide synthesis, and the synthetic peptides are commercially available. Synthetic human gastrin 17, and derivatives such as human gastrin 17 having leucine substituted for methionine at position 15 are also available from Bachem AG, Bubendorf,
  • gastrin compounds may be synthesized by chemical synthesis using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, 1964, J. Am. Chem. Assoc. 85:2149-2154) or synthesis in homogenous solution (Houbenweyl, 1987, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart).
  • the synthesis may be performed using manual procedures or by automation. Automated synthesis may be carried out, for example, using an Applied Biosystems 431 A peptide synthesizer (Perkin Elmer). Gastrin compounds may also be obtained from commercial sources.
  • gastrin 17 with methionine or leucine at position 15 are available from Bachem AG, Bubendorf, (Switzerland), and from Research Plus Inc (New Jersey, USA).
  • Gastrin compounds can be prepared by recombinant methods well known to those skilled in the art.
  • the invention contemplates the use of a nucleotide sequence encoding a gastrin compound, and a host cell comprising the nucleotide sequence for the preparation of a gastrin compound.
  • “Host cells” comprising a nucleotide sequence of a KGF agonist or gastrin compound include a wide variety of prokaryotic and eukaryotic host cells.
  • the polypeptides may be expressed in bacterial cells such as E. coli, Bacillus, or Streptomyces, insect cells (using baculovirus), yeast cells, or mammalian cells.
  • Other suitable host cells can be found in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1991).
  • a host cell may also be chosen which modulates the expression of an inserted nucletotide sequence, or modifies (e.g.
  • Host systems or cell lines may be selected which have specific and characteristic mechanisms for post-translational processing and modification of proteins.
  • cell lines and host systems which stably express the gene product may be engineered.
  • Regulatory element refers to a genetic element or elements having a regulatory role in gene expression, for example, promoters or 1 enhancers, Large numbers of suitable vectors and promoters are known to those of skill in the art and ' are commercially available for generating recombinant constructs encoding a KGF agonist or gastrin compound.
  • the following vectors are provided by way of example.
  • Bacterial pBs, phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (S ratagene); pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia).
  • Eukaryotic pWLneo, pSV2cat, pOG44, PXTL pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia).
  • operably linked means that an isolated polynucleotide and a regulatory element are situated within a vector or cell in such a way that the polypeptide is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/regulatory element sequence.
  • Condition(s) and/or “disease(s)” refer to one or more pathological symptoms or syndromes for which either or both a KGF agonist or a gastrin compound provide a therapeutic effect.
  • the condition or disease may require reduction of blood glucose levels, inhibition of gastric acid secretion, inhibition of apoptosis of ⁇ -cells, stimulation of proliferation or differentiation of ⁇ -cells, and reduction of body weight.
  • conditions and diseases include but are not limited to dyslipidemia, hyperglycemia, severe hypoglycemic episodes, stroke, left ventricular hypertrophy, arrhythmia, bacteraemia, septicaemia, irritable bowel syndrome, functional dyspepsia, diabetes, catabolic changes after surgery, stress induced hyperglycemia, gastric ulcers, myocardial infarction, impaired glucose tolerance, hypertension, chronic heart failure, fluid retentive states, metabolic syndrome and related diseases and disorders, obesity, diabetic complications as well as symptoms of other diseases in which tissue is damaged due to elevated glucose levels, including Alzheimer's Disease, Parkinson's Disease, and other age-related, tissue-degenerative diseases, as well as the artherogenic effects of elevated leptih, for example in patients with impaired glucose tolerance and obese non-diabetic patients.
  • diabetes means any manifested symptoms of diabetes in any mammal including experimental animal models, and including human forms such as type I and type II diabetes, early stage diabetes, and a pre-diabetic condition characterized by mildly decreased insulin or mildly elevated blood glucose levels.
  • a "pre-diabetic condition” describes a subject demonstrating a symptom in terms of insulin or glucose level, and/or demonstrating a susceptibilty to diabetes or a related condition due to family history, genetic predisposition, or obesity in the case of type II diabetes, and includes a subject who has previously had diabetes or a related condition and is subject to risk of recurrence.
  • Insulinotropic activity refers to an ability of a substance to stimulate insulin secretion in response to elevated glucose levels to produce or increase glucose uptake by cells and decreased serum glucose or blood glucose levels. Methods known in the art can be employed to assay for insulinotropic activity. For example, in vitro and in vivo methods may be used that measure KGF receptor binding activity or gastrin receptor binding activity, receptor activation (see the methods described in EP 619,322 to Gelfand et al and US Patent No. 5,120,712), and insulin or C-peptide levels. Compounds, compositions or conjugates described herein have insulinotropic activity if islet cells secrete insulin in the presence of the compounds, compositions, or conjugates above background levels or levels in the absence of the compounds, compositions, or conjugates.
  • a condition or disease includes applications requiring stimulation of epithelial cells, in particular keratinocytes.
  • the conditions may be characterized by damage or deficiencies in these particular cell types.
  • Recombinant KGF has been demonstrated to increase re-epithelialization and increased thickness of the epithelium when topically applied to wounds surgically induced in the rabbit ear or in the porcine skin. (Pierce et al., J. Exp. Med. 179:831-840, 1994); and Staiano-Coico et al., J. Exp. Med. 178:865-878, 1993. Therefore, KGF agonists in combination with a gastrin compound can be used as wound healing agents for burn wounds or to stimulate transplanted corneal tissue.
  • the compounds, compositions and conjugates of the invention may be used to promote and/or enhance soft-tissue growth and regeneration.
  • they may be used to stimulate proliferation and differentiation of adnexal structures such as hair follicles, sweat glands, and sebaceous glands for example, to regenerate epidermis and dermis in' patients with burns and other partial and full thickness injuries.
  • conditions and diseases contemplated herein also include but are not limited to epidermolysis bullosa, chemotherapy induced alopecia, male-pattern baldness, gastric ulcers, duodenal ulcers, inflammatory bowel diseases (e.g.
  • the compounds, compositions and conjugates of the invention may be used to stimulate growth of gastrointestinal mucosa and promote healing after intestinal injury (see Playford, R.J. J. Pathol. 184:316-322, 1998). Therefore, they may have particular application in the treatment of mucositis (loss of gut epithelial tissue after chemotherapy or radiaton therapy for cancer).
  • Islet neogenesis means formation of new beta cells by proliferation and differentiation, which may or may not have the characteristics of stem cells which have the ability to reproduce in an unlimited manner.
  • the invention is related to compositions, conjugates, and methods that utilize a KGF agonist and a gastrin compound, in particular to provide beneficial effects.
  • the compositions, conjugates and methods of the invention provide enhanced beneficial effects, in particular sustained beneficial effects relative to a KGF agonist and/or a gastrin compound alone.
  • the beneficial effects are additive or synergistic.
  • sustained beneficial effects of a composition, combination treatment, or conjugate of the invention may manifest as one or more of the following:
  • pancreatic insulin levels relative to the levels measured in the absence of the active compounds or for each compound alone after administration to a subject with symptoms of diabetes.
  • the compounds together induce at least about a 0.05%, 0.1%, 0.5%, 1%, 2%, 5%, 10%, 15%, 20%, 30%, 33%, 35%, 40%, 45%, 50%, 60%, 70%,
  • pancreatic insulin levels in a subject 80%, 90%, 95%, or 99% increase in pancreatic insulin levels in a subject.
  • the compounds induce at least about a 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% decrease in blood glucose levels. Most preferably, the compounds yield blood glucose levels about or close to the levels common in a normal subject.
  • the compounds together induce at least about a 0.05%, 0.1%, 0.5%, 1%, 2%, 5%, 10%, 15%, 20%, 30%, 33%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% increase in C-peptide levels.
  • a diabetic subject or disease model for example a non-obese (NOD) mouse with symptoms of diabetes.
  • NOD non-obese
  • a gastrin compound is selected for particular embodiments in the present invention and to provide a specific beneficial effect(s) based on characteristics including the ability to augment the activity of a KGF agonist and/or increase the physical or chemical stability of a KGF agonist.
  • a gastrin compound can also be selected based on its ability to stimulate proliferation/differentiation of beta cells, its in vivo half-life, or its insulinotropic activity.
  • the gastrin compound is gastrin 17 and analogs and derivatives thereof.
  • the gastrin compound is synthetic human gastrin I having 17 amino acid residues with a Leu residue at amino acid position 15.
  • a KGF agonist may be selected for particular applications in the present inyention based on one or more of the following characteristics: ability to bind to the KGF receptor, ability to initiate a signal transduction pathway resulting in proliferation and/or differentiation of beta cells or insulinotropic activity; ability to reduce glucose levels, insulinotropic activity; stimulation of beta cell proliferation/differentiation; and/or, an in vivo half-life of at least about 15 minutes to 24 hours, preferably 2 to 10 hours or 2 to 8 hours in humans using conventional methods (see for example, the method described in US 2003/0144206)
  • the KGF agonist is a truncated polypeptide, or an analog or derivative thereof.
  • the sequences of these truncated KGF agonists are represented in US 20030109439, US 5,677,278, WO 3095637, and US 6677301.
  • the KGF agonist is an analog of KGF or KGF-2 which has less than 10 amino acid residues that are different from those in KGF or KGF-2, less than 5 amino acid residues that are different from those in KGF, or less than 3 amino acid residues that are different from those in KGF or KGF-2, preferably only one amino acid residue that is different from sequence of a KGF or KGF-2.
  • KGF agonists that may have specific utility in the present invention include polypeptides where one or more amino' acids have been added to the N-terminus and/or C-terminus of KGF or KGF-2.
  • At least one amino acid of a KGF agonist has at least one substituent attached directly or indirectly (e.g. via a spacer such as ⁇ -Glu or ⁇ -Ala).
  • a substituent is generally selected to make the profile of action of the parent KGF agonist more protracted, make the KGF agonists more metabolically and physically stable, and/or increase solubility of the KGF agonist.
  • An example of a particular substituent is a lipophilic substituent including but not limited to an alkyl group, a group which has an ⁇ -carboxylic acid group, an acyl group of a straight-chain or branched fatty acid or alkane such as tetradecanoyl, hexadecanoyl.
  • the KGF agonist is selected from the group consisting of KGF-1 and KGF-2.
  • the invention contemplates a composition, preferably a pharmaceutical composition, comprising a KGF agonist and a gastrin compound, in particular a gastrin/CCK receptor ligand.
  • a pharmaceutical composition may optionally comprise a pharmaceutically acceptable carrier, excipient, or vehicle.
  • the composition provides beneficial effects relative to each compound alone.
  • the invention contemplates a pharmaceutical composition comprising a KGF agonist and a gastrin compound, in particular a gastrin/CCK receptor ligand, which provides beneficial effects, preferably sustained beneficial effects, following treatment.
  • a KGF agonist and a gastrin compound in a composition of the invention may be in a ratio selected to augment the activity of the agonist and/or gastrin compound to provide a beneficial effect.
  • the invention also provides a pharmaceutical composition in separate containers and intended for simultaneous or sequential administration to provide beneficial effects, comprising a KGF agonist and a gastrin compound, both optionally together with pharmaceutically acceptable carriers, excipients, or vehicles.
  • compositions of the invention can be selected that have statistically significant sustained beneficial effects, preferably sustained beneficial effects, compared with a KGF agonist or a gastrin compound alone.
  • a pharmaceutical composition with statistically significant beneficial effects comprising a KGF agonist selected from the group consisting of KGF and KGF-2, and a gastrin compound selected from the group consisting of gastrin 17 and analogs and derivatives thereof, preferably synthetic human gastrin I having 17 amino acid residues with a Leu residue at amino acid position 15.
  • a pharmaceutical composition with statistically significant beneficial effects comprising KGF and gastrin- 17(1 eu).
  • the invention comprises pharmaceutically acceptable salts of a KGF agonist and/or pharmaceutically acceptable salts of a gastrin compound.
  • a pharmaceutical composition which has been adapted for administration to a subject to provide sustained beneficial effects to treat a condition or disease, preferably diabetes. In a preferred embodiment, it is in a form such that administration to a subject results in blood glucose levels that are about normal that persist in the subject for a prolonged period of time after cessation of treatment.
  • a composition comprising a KGF agonist and a gastrin compound have greater sustained insulinotropic activity following treatment compared with the activity of a KGF agonist or gastrin compound alone or greater than KGF alone. Conjugates
  • This invention provides a conjugate comprising a KGF agonist linked to a gastrin compound wherein the linkage is, for example, via an amino or carboxyl group.
  • the invention also relates to isolated covalent conjugates of the invention, and compositions comprising covalent conjugates of the invention.
  • a KGF agonist may be conjugated to a species via an ester bond between a OH and a COOH of a gastrin compound.
  • Conjugates of a KGF agonist and a gastrin compound may be conjugated or linked with an intermediate spacer or linker.
  • a suitable spacer or linker may be a mono- or disaccharide, an amino acid, a sulfate, a succinate, an acetate, or an oligomeric polymeric spacer or linker comprising one or more of such moieties.
  • the invention also provides methods of preparing the above covalent conjugates that result in conjugates with improved pharmacokinetic properties, biological activity, and beneficial effects.
  • the methods comprise incubating or reacting the KGF agonist with the gastrin compound under conditions that allow formation of a covalent linkage between the two compounds.
  • the invention therefore contemplates a process for preparing a covalent conjugate , comprising a
  • KGF agonist covalently bonded or linked to a gastrin compound the process comprising: incubating or reacting the KGF agonist with a gastrin compound under conditions and at a pH and for a time sufficient for formation of a covalent bond or linkage between the KGF agonist and gastrin compound; and isolating the covalent conjugate.
  • N-terminal or C-terminal fusion proteins or chimeric proteins comprising a KGF agonist conjugated with a gastrin compound, optionally with a spacer or linker, may also be prepared by fusing, through recombinant techniques, the N-terminal or C-terminal sequence of a KGF agonist and the sequence of a gastrin compound.
  • the invention also provides a conjugate prepared by a process described herein.
  • the invention also relates to pharmaceutical formulations comprising conjugates of the invention and a pharmaceutically acceptable carrier, excipient, or vehicle.
  • the invention further relates to a pharmaceutical formulation of a substantially pure covalent conjugate comprising a KGF agonist covalently linked to a gastrin compound which provides beneficial effects, preferably sustained beneficial effects, compared to the KGF agonist alone.
  • a pharmaceutical formulation is provided consisting essentially of covalent conjugates comprising a KGF agonist covalently linked without an intermediate spacer or linker to a gastrin compound.
  • the invention also contemplates the use of a composition of the invention or combination treatment of the invention for preventing, and/or ameliorating disease severity, disease symptoms, and/or periodicity of recurrence of a disease or condition described herein.
  • the invention also relates to the prevention and treatment, in mammals, of conditions or diseases using the compositions, combination treatments, and conjugates of the invention.
  • the invention provides a combination treatment for preventing and/or treating a condition or disease in a subject comprising administering to the subject a therapeutically effective amount of at least one KGF agonist and at least one gastrin compound to produce beneficial effects, preferably sustained beneficial effects.
  • the present invention includes combination treatments providing additive or synergistic activity, delivering an additive or synergistically effective amount, or an amount to provide a therapeutically effective amount of a KGF agonist and a gastrin compound, or a conjugate or composition of the invention. Therefore, pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in a synergistically effective amount or a therapeutically effective amount.
  • KGF and a gastrin compound to treat diabetes in one embodiment provides a combination of gastrin with KGF to achieve greater efficacy, potency, and utility than achieved with KGF alone, resulting in an improved therapeutic ratio for combination.
  • the greater efficacy can be shown by improving glucose tolerance in severe diabetes with treatment resulting in prolonged improvement of blood glucose after ceasing treatment (Example 6) and also in recent onset diabetes (Example 7).
  • Treatment with a combination of gastrin and KGF can provide a reduction in blood glucose that is • greater than observed after treatment with KGF alone, and the reduction can be sustained for prolonged periods after ceasing treatment in severe diabetes (Example 5) and recent onset diabetes (Example 7).
  • systemic administration of KGF can have greater potency than when KGF is administered alone.
  • An improvement in glucose tolerance is observed with the KGF/gastrin combinations using lower doses of KGF that are not effective when administered alone, i.e. doses below 1 mg/kg body weight.
  • gastrin and KGF improves the therapeutic ratio of treatment, since use of the lower doses of KGF reduces untoward side effects and toxicity resulting from KGF induced proliferation of other organs such as the liver.
  • the combination also enhances utility improving long-standing diabetes even when treatment is begun long after the completion of ⁇ cell destruction (see Example 1 and 2).
  • the gastrin/KGF combination can be effective in reducing blood glucose with treatment initiated as long as 3-4 weeks after streptozotocin-induced ⁇ cell destruction.
  • the invention also relates to a method of treatment comprising administering a therapeutically effective amount of at least one KGF agonist in combination with the administration of at least one gastrin compound which upon administration to a subject with symptoms of diabetes produces beneficial effects, preferably sustained beneficial effects, manifested as reduced blood glucose levels and/or increased pancreatic insulin.
  • therapeutically effective amounts of a KGF agonist and a gastrin compound are combined prior to administration to a subject.
  • therapeutically effective amounts of a KGF agonist and a gastrin compound are mixed at a physiologically acceptable pH.
  • the invention provides a method for preventing and or treating Type I or Type II diabetes comprising administering a therapeutically effective amount of a composition or conjugate of the invention, or administering in combination a KGF agonist and a gastrin compound.
  • the invention provides a method for amelioriating progression of disease or obtaining a less severe stage of disease in a person suffering from Type I or Type II diabetes comprising administering a therapeutically effective amount of a composition or conjugate of the invention, or administering in combination a KGF agonist and a gastrin compound.
  • the invention relates to a method of delaying the progression of impaired glucose tolerance or non- insulin requiring Type II diabetes to insulin requiring Type II diabetes comprising administering a therapeutically effective amount of a composition or conjugate of the invention, or administering in combination a KGF agonist and a gastrin compound.
  • the invention also relates to a method of increasing the insulin synthesis capability of a subject comprising administering a therapeutically effective amount of a composition or conjugate of the invention, or administering in combination a KGF agonist and a gastrin compound.
  • the expanded ⁇ cell mass decreases to non-pregnant levels along with the decrease in prolactin and placental lactogen ((Logothetopoulos, J. (1972) in Handbook of Physiology (Am. Physiol. Soc, Washington, DC), Section 7 Chapter 3, pp. 67-76).
  • prolactin and placental lactogen (Logothetopoulos, J. (1972) in Handbook of Physiology (Am. Physiol. Soc, Washington, DC), Section 7 Chapter 3, pp. 67-76).
  • the invention provides a method for stimulating beta cell proliferation in a subject comprising administering a therapeutically effective amount of a composition or conjugate of the invention, or administering in combination a KGF agonist and a gastrin compound.
  • the invention provides a method for increasing the number and/or size of beta cells in a subject comprising administering a therapeutically effective amount of a composition or conjugate of the invention or administering in combination a KGF agonist and a gastrin compound.
  • a method for treating diabetes mellitus in an individual in need thereof includes administering to the individual a composition that provides both a gastrin/CCK receptor ligand and a KGF receptor ligand, in doses sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin- secreting cells.
  • a method for treating insulin dependent diabetes, especially Type I or juvenile diabetes mellitus comprises administering, preferably systemically, a differentiation regenerative amount of both a gastrin/CCK receptor ligand and a KGF receptor ligand, to a diabetic mammal, to stimulate islet neogenesis to increase the number of functional glucose responsive insulin secreting ⁇ cells in the pancreas.
  • gastrin and KGF receptor ligand would result in significant enhancement of the islet neogenesis response over that observed with either of the gastrin or the KGF receptor ligand alone.
  • a preferred gastrin/CCK receptor ligand is gastrin, and a preferred KGF receptor ligand is KGF (FGF-7) or KGF-2 (FGF-10).
  • Another embodiment is a method comprising treating cells, or treating explanted pancreatic tissue of a mammal with a gastrin/CCK receptor ligand and KGF receptor ligand and introducing the treated cells or pancreatic tissue to the mammal.
  • the preferred gastrin/CCK receptor ligand is gastrin and the preferred KGF receptor ligand is KGF (FGF-7) or KGF-2(FGF-10).
  • the invention provides a method for gastrin/CCK receptor ligand stimulation comprising providing a chimeric insulin promoter- gastrin fusion gene to pancreatic cells and expressing the gene.
  • a method of KGF receptor ligand stimulation comprising expression of a KGF receptor ligand gene transgenically introduced into a mammal, for example, a KGF receptor ligand is KGF (FGF-7) similarly provided as in US Patent No. 5,885,956.
  • the invention provides a method for treating diabetes mellitus by administering a composition comprising both a gastrin/CCK receptor ligand, e.g. gastrin, and a KGF receptor ligand, e.g. KGF, KGF-2, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells.
  • Both ligands in the composition can be administered systemically.
  • one or both ligands can be expressed in situ by cells provided with a nucleic acid fusion construct in an expression vector.
  • the fusion construct typically includes a preprogastrin peptide precursor coding sequence, and also a coding sequence for a KGF receptor ligand.
  • Prolonged efficacious islet cell neogenesis is achieved following administration of both a gastrin/CCK receptor ligand, such as gastrin, and a growth factor ligand of the KGF tyrosine kinase receptor (TKR) family, such as KGF.
  • a gastrin/CCK receptor ligand such as gastrin
  • a growth factor ligand of the KGF tyrosine kinase receptor (TKR) family such as KGF.
  • pancreatic precursor cells for example, pancreatic ductal cells
  • mature insulin-secreting cells is obtained with the provided compositions, conjugates, and methods for treatment of diabetes mellitus, particularly juvenile onset diabetes, and by therapeutic administration of this combination of factors or compositions which are provided for systemic administration, or for in situ expression within the pancreas.
  • the invention provides methods for treating cells, preferably cells in culture using a KGF agonist and gastrin compound of the invention, or compositions, or conjugates of the invention.
  • the invention also provides cell based treatment methods using a KGF agonist and gastrin compound of the invention, or compositions, or conjugates of the invention. See PCT/CA03/33595 for a description of general culture and cell based treatment methods.
  • the invention provides a method of treating a condition or disease comprising administering a KGF agonist and a gastrin compound, a composition or conjugate of the invention with a plurality of cells to a subject in need thereof to thereby produce a beneficial effect, preferably a sustained beneficial effect.
  • a method for treating a subject with a condition or disease described herein comprises contacting ex vivo a plurality of cells with a KGF agonist and a gastrin compound, or a composition or conjugate of the invention of the invention, optionally culturing the cells, and administering the cells to the subject in need thereof.
  • the cells are pancreatic ductal cells and the amount of compounds/composition/conjugate used in the method is generally effective to increase the amount of insulin secreting cells in the subject.
  • the cells may be autologous (i.e. from the same subject), or may be from another individual of the same species, or from a different species.
  • the invention also relates to inducing islet neogenesis in a subject comprising contacting islet precursor cells with a KGF agonist and a gastrin compound, composition, or conjugate of the invention in a sufficient amount to increase proliferation of islet precursor cells in the subject thereby inducing islet neogenesis.
  • the invention also relates to a method for expanding and differentiating stem cells into insulin secreting cells comprising contacting the stem cells with an effective amount of a KGF agonist and a gastrin compound or a composition or conjugate of the invention.
  • the compounds, composition or conjugates may be administered to a subject before, during, or after stem cells are implanted in the subject.
  • the stem cells may be obtained from pancreatic islets, umbilical cords, embryos, or stem cell lines.
  • the method may additionally comprise administering an immunosuppressive agent.
  • the invention contemplates a method of expanding a functional beta cell mass of pancreatic islet transplants in a diabetic patient, the method comprising administering to the patient a therapeutically effective amount of a KGF agonist and a gastrin compound, or a composition or conjugate of the invention.
  • the invention also contemplates a method for treating diabetes in a subject comprising transplanting a pancreatic islet preparation into the subject and administering a therapeutically effective amount of a KGF agonist and a gastrin compound, or a composition or conjugate of the invention.
  • the methods of the invention may further comprise measuring one or more of the following markers: blood glucose, serum glucose, blood glycosylated haemoglobin, pancreatic beta cell mass, serum insulin, pancreatic insulin levels, morphometrically determined beta cell mass, amount of insulin secreting cells, and glucose responsiveness of insulin secreting cells.
  • the invention also contemplates the use of a composition comprising a combination of at least one KGF agonist and at least one gastrin compound for the preparation of a medicament providing beneficial effects, preferably sustained beneficial effects in treating a condition or disease.
  • the invention relates to the use of a therapeutically effective amount of at least one KGF agonist, and at least one gastrin compound for preparation of a medicament for providing beneficial effects, preferably sustained beneficial effects, in treating a condition or disease.
  • the invention provides the use of a KGF agonist and a gastrin compound for the preparation of a medicament for increase (preferably sustained increase) of the number and/or size of beta cells in a subject after treatment.
  • the invention provides the use of KGF agonist and a gastrin compound for the preparation of a medicament for stimulation (preferably sustained stimulation) of beta cell proliferation after treatment.
  • the invention provides the use of KGF and gastrin for the preparation of a medicament for treatment of Type I or Type II diabetes.
  • the invention additionally provides uses of a pharmaceutical composition and a conjugate of the invention in the preparation of medicaments for beneficial effects, preferably sustained beneficial effects, in the treatment of diseases and conditions.
  • compositions, conjugates and methods or the invention may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals such as by calculating a statistical parameter such as the ED 50 (the dose that is therapeutically effective in 50% of the population) or LD 50 (the dose lethal to 50% of the population) statistics.
  • the therapeutic index is the dose ratio of therapeutic to toxic effects and it can be expressed as the ED S0 / O S0 ratio.
  • Pharmaceutical compositions which exhibit large therapeutic indices are preferred.
  • the present invention also includes methods of using the compositions of the invention in combination with one or more additional therapeutic agents including without limitation immunosuppressive agents (e.g.
  • rapamycin cyclosporine, ISAtx247, and FK506
  • antiobesity agents antidiabetic agents
  • appetite regulating drugs antihypertensive agents
  • agents for the treatment and/or prevention of complications resulting from or associated with a condition or disease in particular diabetes and obesity, anti-nausea, anti- headache medications, and general medications that treat or prevent side effects
  • a gastrin compound in combination with a KGF agonist, conjugates, and compositions of the present invention can be administered by any means that produce contact of the active agent(s) with the agent's sites of action in the body of a subject or patient.
  • the active ingredients can be administered simultaneously or sequentially and in any order at different points in time, to provide the desired beneficial effects.
  • the compounds, conjugates and compositions can be formulated for sustained release, for delivery locally or systemically. It lies within the capability of a skilled physician or veterinarian to select a form and route of administration that optimizes the effects of the compositions, conjugates, and treatments of the present invention.
  • Modes of parenteral administration include, but are not limited to, transdermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, and oral routes.
  • the compounds may be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g. oral mucosa, rectal and intestinal mucosa, etc.), and may be administered together with other biologically active agents.
  • a preferred route of administration is systemic, for example, by subcutaneous injection.
  • the compounds or conjugates described herein may be combined with saline, PBS, or other suitable buffer, at an appropriate pH.
  • a sustained release formulation can also be used for either or both therapeutic agents.
  • compositions may be administered in oral dosage forms such as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. They may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular forms, all utilizing dosage forms well known to those of ordinary skill in the pharmaceutical arts.
  • the compositions of the invention may be administered by intranasal route via topical use of suitable intranasal vehicles, or via a transdermal route, for example using conventional transdermal skin patches.
  • a dosage protocol for administration using a transdermal delivery system may be continuous rather than intermittent throughout the dosage regimen.
  • the dosage regimen of the invention will vary depending upon known factors such as the pharmacodynamic characteristics of the agents and their mode and route of administration; the species, age, sex, health, medical condition, and weight of the patient, the nature and extent of the symptoms, the kind of concurrent treatment, the frequency of treatment, the route of administration, the renal and hepatic function of the patient, and the desired effect.
  • the effective amount of a drug required to prevent, counter, or arrest progression of a condition can be readily determined by an ordinarily skilled physician or veterinarian.
  • An amount of a therapeutic of the invention which will be effective in the treatment of a particular condition or disorder will depend on the' nature of the condition or disorder, and can be determined by standard clinical techniques.
  • the precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the condition or disorder, and should be decided according to the judgement of the practitioner and each patient's circumstances. Routine determinations of blood levels of insulin or C peptide, and of fasting levels of glucose or glucose challenges, are determined by one of ordinary skill in the art.
  • Suitable dosage ranges for administration are generally about 0.01 micrograms to about 10,000 micrograms of each active compound per kilogram body weight per day, for example, about 0.01 micrograms to about 1 microgram kg, about 0.1 micrograms/kg to about 10 micrograms/kg, about 1 microgram/kg to about 500 micrograms/kg, or about 10 micrograms/kg to about 10 mg/kg of body weight per day. Suitable dosage ranges for administration are thus generally about 0.01 micrograms/kg body weight/day to about 10 mg/kg body weight/day. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • a composition or treatment of the invention may comprise a unit dosage of at least one KGF agonist and a unit dosage of at least one gastrin compound.
  • a "unit dosage” refers to a unitary i.e. a single dose which is capable of being administered to a patient, and which may be readily handled and packed, remaining as a physically and chemically stable unit dose comprising either the active agents as such or a mixture with one or more solid or liquid pharmaceutical excipients, carriers, or vehicles.
  • a pharmaceutical composition comprising a therapeutically effective suboptimal dosage of a KGF agonist and a gastrin compound that are more effective at decreasing or reducing glucose levels for a sustained period or increasing beta cell proliferation or differentiation following treatment compared with a dosage of either a gastrin compound or KGF agonist alone.
  • an improved pharmaceutical composition comprising therapeutically effective suboptimal amounts of a KGF agonist and a gastrin compound in a form for chronic or acute therapy of a disease or condition, in particular diabetes.
  • the composition comprises a KGF agonist and a gastrin compound in doses that are equal to or at least 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, or 10 fold lower than the doses of each compound required to provide beneficial effects, preferably sustained beneficial effects, to treat a disease or condition.
  • the invention provides a pharmaceutical composition comprising between 0.5 to 6000, 100-1500, 100-6000, 1000-6000, 2000-6000, and 3000-6000 micrograms KGF agonist per single unit and 0.5 to 6000, 100-3000, 100-6000, 1000-6000, 2000-6000, and 3000-6000 micrograms gastrin compound per single unit.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising between 0.1 to 20, 0.1 to 30, 0.1 to 40, 0.1 to 50, and 0.1 to 100 micrograms/kg/day KGF agonist and 0.1 to 20, 0.1 to 30, 0.1 to 40, 0.1 to 50, and 0.1 to 60 micrograms/kg/day gastrin compound.
  • a composition or formulation of the invention may be administered to a subject for 2 weeks to 12 months, 2 weeks to 6 months, 2-16 weeks, 2 weeks to 12 weeks, and/or 2-8 weeks, or periodically.
  • the ratio of KGF agonist to gastrin compound in a composition of the invention is selected to augment the activity of the KGF agonist and/or gastrin compound and to provide beneficial effects, preferably sustained beneficial effects.
  • a KGF agonist and a gastrin compound may be in a ratio selected to augment the activity of one or both compounds to produce beneficial effects, preferably an additive or synergistic effect, or beneficial effects, preferably sustained beneficial effects.
  • the ratio of a KGF agonist to a gastrin compound may be from 1:1 to 1:110, 1:1 to 1:100, 1:1 to 1:75, 1:1 to 1:50, 1:1 to 1:25, 1:1 to 1:10, 1:1 to 1:5, and 1:1.
  • the ratio of a gastrin compound to a KGF agonist may be from 1:1 to 1:110, 1:1 to 1:100, 1:1 to 1:75, 1:1 to 1:50, 1:1 to 1:25, 1:1 to 1:10, and 1:1 to 1:5.
  • a KGF agonist may be used in combination with a gastrin compound at therapeutically effective weight ratios of between about 1:1 to 1:150, preferably 1:1 to 1:50.
  • a gastrin compound may be used in combination with a KGF agonist at therapeutically effective weight ratios of between about 1:1 to 1:150, preferably 1:1 to 1:50.
  • compositions of the present invention or fractions thereof typically comprise suitable pharmaceutical diluents, excipients, vehicles, or carriers selected based on the intended form of administration, and consistent with conventional pharmaceutical practices.
  • suitable pharmaceutical diluents, excipients, vehicles, or carriers selected based on the intended form of administration, and consistent with conventional pharmaceutical practices.
  • the carriers, vehicles etc. may be adapted to provide an additive, synergistically effective or therapeutically effective amount of the active compounds.
  • Suitable pharmaceutical diluents, excipients, vehicles, and carriers are described in the standard text, Remington's Pharmaceutical Sciences, Mack Publishing Company.
  • the active components can be combined with an oral, non- toxic pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, methyl cellulose, magnesium stearate, glucose, calcium sulfate, dicalcium phosphate, mannitol, sorbital, and the like.
  • the drug components may be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like.
  • Suitable binders e.g.
  • compositions as described herein can further comprise wetting or emulsifying agents, or pH buffering agents.
  • the composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder.
  • the compositions can be formulated as a suppository, with traditional binders and carriers such as triglyce'rides.
  • Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.
  • Various delivery systems are known and can be used to administer a composition of the invention, e.g. encapsulation in liposomes, microparticles, microcapsules, and the like.
  • a pharmaceutical composition has a pH from about 7 to 10.
  • Formulations for parenteral administration of a composition of the invention may include aqueous solutions, syrups, aqueous or oil suspensions and emulsions with edible oil such as cottonseed oil, coconut oil or peanut oil.
  • Dispersing or suspending agents that can be used for aqueous suspensions include synthetic or natural gums, such as tragacanth, alginate, acacia, dextran, sodium carboxymethyl cellulose, gelatin, methylcellulose, and polyvinylpyrrolidone.
  • compositions for parenteral administration may include sterile aqueous or non-aqueous solvents, such as water, isotonic saline, isotonic glucose solution, buffer solution, or other solvents conveniently used for parenteral administration of therapeutically active agents.
  • a composition intended for parenteral administration may also include conventional additives such as stabilizers, buffers, or preservatives, e.g. antioxidants such as methylhydroxybenzoate or similar additives.
  • compositions herein are formulated in accordance with routine procedures as a pharmaceutical composition adapted for subcutaneous or intravenous administration to human beings.
  • compositions for subcutaneous or intravenous administration are solutions in sterile isotonic aqueous buffer.
  • the composition may also include a solubilizing agent and a local anesthetic to ameliorate pain at the site of the injection.
  • the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry, lyophilized powder or water-free concentrate in a hermetically sealed container such as an ampoule or sachette, for example, indicating the quantity of active agent.
  • an ampoule of sterile water or saline for injection can be provided so that the ingredients may be mixed prior to administration.
  • compositions of the invention can be formulated as neutral or salt forms.
  • Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2- ethylamino ethanol, histidine, procaine, etc.
  • a solid form pharmaceutical composition comprising a crystalline or amorphous KGF agonist and a gastrin compound.
  • a solid form pharmaceutical composition is provided (e.g. tablets, capsules, powdered, or pulverized form) comprising a crystalline or amorphous a crystalline or amorphous gastrin compound and a KGF agonist.
  • the invention relates to a liquid drug formulation comprising pharmaceutically acceptable salts of a KGF agonist and a gastrin compound, and to lyophilized drug formulations that can be reconstituted to provide suspensions that are stable and suitable for parenteral administration.
  • the invention relates to an aqueous composition
  • a aqueous composition comprising pharmaceutically acceptable salts of a KGF agonist and a gastrin compound, and a solvent system which effects solubilization.
  • the invention also provides a drug comprising an aqueous formulation of pharmaceutically acceptable salts of a KGF agonist and a gastrin compound with at least one solubilizer.
  • a composition of the invention may be sterilized by, for example, filtration through a bacteria retaining filter, addition of sterilizing agents to the composition, irradiation of the composition, or heating the composition.
  • the compounds, conjugates, and compositions of the present invention may be provided as sterile solid preparations e.g. lyophilized powder, which are readily dissolved in sterile solvent immediately prior to use.
  • compositions can also be formulated as a depot preparation.
  • Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
  • the fractions may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil), or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • suitable polymeric or hydrophobic materials for example, as an emulsion in an acceptable oil
  • ion exchange resins for example, as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the compositions of the invention and components thereof may comprise soluble polymers as targetable drug carriers.
  • compositions After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labelled for treatment of an indicated condition.
  • labelling would include amount, frequency, and method of administration.
  • the present invention relates to a method of treatment comprising a combination of active agents which may be administered separately or as conjugates or as compositions
  • the invention also provides a kit comprising a KGF agonist and a gastrin compound, a pharmaceutical composition or conjugate in kit form.
  • the invention also provides a pharmaceutical kit comprising one bottle with a KGF agonist and another bottle with a gastrin bottle in one box.
  • a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of a pharmaceutical composition of the invention.
  • Associated with such container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use, or sale for human . administration.
  • kits are provided.
  • the kit is a package which houses a container which contains a covalent conjugate of the invention and also houses instructions for administering the covalent conjugate to a subject.
  • the invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner.
  • mice Male Wistar rats will be injected with 30 mg/kg of streptozotocin intravenously (iv.) on three consecutive days. Glycemia will be controlled by insulin pellets implanted subcutaneously before treatment (one pellet per rat). Blood glucose measurements will be taken prior to implanting insulin pellets subcutaneously (sc) and non-fasting blood glucose levels will be monitored to determine the degree of glucose control.
  • the KGF and gastrin combination (50 and 300 ⁇ g/kg, respectively) will be administered as a subcutaneous bolus injection 3 times daily for 4 weeks, commencing three weeks after injection of the STZ injection. An intraperitoneal glucose tolerance test (IPGTT) will be conducted 6 days after cessation of treatment. Further, C-peptide and pancreatic insulin can be assessed.
  • IPGTT intraperitoneal glucose tolerance test
  • treating rats with a composition which is a combination of KGF/gastrin should improve the non fasting blood glucose level in diabetic rats, compared to those treated with vehicle alone. Further, following an intraperitoneal glucose challenge, blood glucose should return to a more normal level more quickly in the KGF and gastrin treated rats.
  • Example 3 Assay of glucose tolerance and insulin secretion Using the streptozotocin rats from Example 1, it can be demonstrated that treatment with KGF/gastrin combination should improve insulin secretion and C peptide release. Improvement in glucose tolerance of the diabetic rats treated with KGF/gastrin should result from increased insulin secretion.
  • KGF Gastrin treatment increases pancreatic ⁇ cell mass Rats will be made diabetic with 65mg kg streptozotocin (STZ) at a time point 10 days prior to treatment, the treatment comprising 250 ⁇ g/kg of KGF each day and 250 ⁇ g/kg each day of gastrin, administered by subcutaneous infusion for 2 weeks.
  • An identically diabetic control group will receive vehicle by a subcutaneous infusion route similar to that of the KGF/gastrin group.
  • the rats will be sacrificed and the pancreas will be collected for insulin determination and ⁇ cell mass determination.
  • the ⁇ -cell mass will be determined by point counting morphometrics according to the following protocol. Paraffin sections (5 ⁇ ih) are immunoperoxidase stained for insulin determination. Diaminobenzidine is used as the substrate for peroxidase and slides are counterstained only with hematoxylin. One section from each pancreas is examined by point counting. A rectangular 16x12 point grid is used, total 192 points. Each pancreas section is counted using the lOx magnification lens. The field is projected to a computer screen, final magnification 265x. At this magnification the diameter of Beta-cells is 3-5 mm. Total number of points counted per section is typically 11,000 - 20,000 depending on the size of the section.
  • the ⁇ -cell content is calculated by dividing the number of points falling on insulin stained cells by the total number of points falling on pancreatic tissue. The ⁇ -cell content is expressed as a percent. The ⁇ - cell mass is calculated by multiplying ⁇ -cell content (%) with the weight of the pancreas, in mg. Pancreatic insulin content is determined by immunoassay of ethanol water extracts of pancreas.
  • STZ causes severe depletion of ⁇ -cell mass in comparison to those in normal (untreated) rats.
  • After 7 days of treatment with the KGF/Gas rin combination there should be an increase in ⁇ cell mass.
  • a correlation should also be obtained between ⁇ -cell mass and insulin content.
  • pancreatic insulin content will result from a greater ⁇ -cell mass.
  • Rats will be made diabetic with streptozotocin administered intravenously (60 mg/kg), and 14 days later (rather than the 21 day interval of Examples, supra), rats will be distributed into 4 groups: 10 ⁇ g/kg KGF administered via the intraperitoneal route (ip) twice daily, 10 ⁇ g/kg Gastrin ip twice daily, combination of each of 10 ⁇ g/kg KGF and 10 ⁇ g/kg Gastrin ip twice daily, or Vehicle ip twice daily.
  • treated Stz rats should show prolonged improvement of levels of fasting blood glucose, compared to untreated diabetic rats in the vehicle group (STZ rats having a similar level of diabetes before treatment with vehicle alone). Rats will be treated with 10 ⁇ g/kg KGF and 10 ⁇ g/kg gastrin by ip injection twice daily for 10 days, The rats will be followed for up to 4 months measuring both the fasting blood glucose and the glucose tolerance after an IPGTT. Treatment of rats with a KGF/Gastrin combination will cause a significant reduction in fasting blood glucose compared to the untreated diabetic STZ rats, so that the fasting blood glucose level more resembles that of the non-diabetic control rats. Even at a time such as four months after treatment, blood glucose in treated STZ rats should be significantly lower than that of untreated control rats.
  • Example 7 Treatment with KGF and gastrin prevents disease progression in NOD mice with recent-onset diabetes.
  • the non-obese diabetic (NOD) strain of mouse is an excellent model of autoimmune (type 1) diabetes, as the phenotype mirrors many features of disease pathogenesis in the human form of type I diabetes.
  • NOD mice typically exhibit destructive autoimmune pancreatic insulitis and ⁇ -cell destruction as early as four weeks of age. Diabetes onset usually occurs at age 10-15 weeks in these mice, with typical blood glucose levels observed to be between 7-10 mM (compared to a range of about 3.0-6.6 mM normal mice), and a pancreatic insulin level lower by more than about 95% than that in normal mice.
  • NOD mice exhibit increasingly severe signs of chronic diabetes, with blood glucose levels reaching between about 25 to about 30 mM and pancreatic insulin level declining to become virtually nonexistent. At that severe stage of the disease, greater than about 99% of the ⁇ -cells have been destroyed.
  • the effect of treatment by a combination of KGF + gastrin is examined in NOD mice with recent onset diabetes.
  • the objective is to determine whether administration of low doses of both KGF and gastrin prevents severe hyperglycemia and increases pancreatic insulin content in NOD mice with recent-onset diabetes.
  • Gastrin is synthetic human gastrin I having 17 amino acid residues with a Leu residue at amino acid position 15, and KGF is recombinant human KGF.
  • Non-obese diabetic (NOD) female mice ages 10-12 weeks, will be monitored for development of onset of diabetes (fasting blood glucose > 6.6 mmol/1), and within 36 hours after onset of symptoms, each of three groups of mice will be treated as follows: with vehicle; with 0.25 ⁇ g/kg/day of KGF; with 1.5 ⁇ g/kg/day of gastrin; or with 0.25 ⁇ g/kg/day of KGF + 1.5 ⁇ g/kg/day of gastrin, each treatment administered via the i.p. route twice daily.
  • a range of from about 0.1 ⁇ g/kg/day to about 100 ⁇ g/kg/day of KGF and a range of about 1 ⁇ g/kg/day to about 60 ⁇ g/kg/day of gastrin can be used.
  • Therapy is administered for 14 - 28 days.
  • animals are maintained untreated for an additional 10-14 days, and are sacrificed so as to determine whether prevention of severe hyperglycemia persists after termination of therapeutic treatment.
  • Mice receive neither insulin-replacement treatment nor immunosuppression. The following parameters are assessed: survival rates, status of liver function, pancreatic insulin levels, and fasting blood glucose levels.
  • the Examples can show that treatment with a short course of low doses of KGF and gastrin treatment in mice with recent onset of diabetes prevents disease progression and improves pancreatic insulin content, and these effects are sustained for a prolonged period of time after termination of therapy.
  • Treatment with the combination of KGF and gastrin is expected to yield a reduction in fasting blood glucose levels and an increase in pancreatic insulin content that is greater than the changes in these parameters in mice treated with KGF alone.
  • a lower concentration of KGF can be used in combination with gastrin than alone, which can ameliorate the known side effects of KGF at higher concentrations.
  • KGF and gastrin Treatment with KGF and gastrin prevents and or compensates for the autoimmune destruction of pancreatic islet ⁇ -cells, thereby maintaining the ⁇ -cell mass and pancreatic insulin content at a level sufficient to prevent severe hyperglycemia, ketoacidosis, and death. Further, administration of both KGF and gastrin prevents progression in mice with recent-onset diabetes, without concurrent insulin replacement and immunosuppression.
  • Example 8 Effects of Gastrin and Keratinocyte Growth Factor (KGF) in treating Acutely-Diabetic Non- Obese Diabetic (NOD') Mice
  • KGF Keratinocyte Growth Factor
  • fibroblast Figures 9 & 10 having higher loop-forming ARAKA , growth factor potential for an amino acid residue of Tsutomu; having enhanced lower loop-forming potential in or about FOX, Gary, stability and the loopforming sequence Asn-His-Tyr-Asn- Michael; biological Thr-Tyr of the naturally occurring protein. activity
  • growth factor residues corresponding to amino acid MORRIS positions 1 and 15 of the KGF amino acid Charles, F.; positions 32 and 46 of SEQ ID No: 2, (Cys ⁇ l> KENNEY, and Cys ⁇ 15>, respectively) are deleted or William, C; substituted with another amino acid CHEN, Bao-Lu; HSU, Eric, Also listed are: C(1,15)S, NA15, NA16, NA17, NA18, NA19, NA20, NA21, NA22, NA23
  • EP0935652B1 Keratinocyte KGF-2 defined by amino acids Cys37 to growth factor-2 Ser208 of SEQ ID NO: 2 and variant proteins
  • Inventors products thereof, including a protein in which one NARHI, Linda, or more amino acid residues have been Owens ; deleted from, inserted into, and/or OSSLUND, substituted for residues within the amino Timothy, D. acid sequence of SEQ ID NO: 2 and which retains biological activity
  • US20040043924A1 W09816642A1 includes the above with the following included in the claims section: Rl-[Asn71-Pro203]-C00H proteins where a ' long list of possible amino acids representing Rl includes Tyr Ser-Tyr Arg- Ser-Tyr Val-Arg-Ser-Tyr (SEQ ID NO: 9) and many others and R2 carboxy terminal amino acids
  • KGF growth factor Gospodarowicz, (KGF) having Deletion of KGF reported to show increased Denis J. increased biological activity and less cytotoxicity Masiarz, Frank biological to epithelial cells R.; activity
  • keratinocyte least a two-fold increase in mitogenic growth factor activity over kgfl63
  • WO9501434A1 cells useful for stimulating wound healing and treating epidermal hyper :proliferat ion US5677278 Truncated As in WO03095637A1 (above) keratinocyte
  • KGF polypeptides include KGF desl-15 i.e. . compositions amino acids 16-163, KGFdesl-18 through to
  • KGFdesl-22, KGFdesl-24 and KGFdesl-25 also Gospodarowicz, Derwent Title: biologically active analogues of these, Denis J. ; Use of the where these biologically active analogues Kavanaugh, . keratinocyte consists of the same number of amino acids Michael; growth factor respectively, and have at least 70% Crawford, polypeptide for sequence homology and exhibits an increase Kenneth the manufacture in bioactivity relative to mature, full- of a medicament length, KGF (KGF163)
  • Combination KGF refers to any one of a mature pdgf, kgf, igf polypeptide and biologically active
  • Chiron US6693077 Keratinocyte Includes : growth factor 2. recombinant, natural and synthetic forms of KGF-2, fragment, derivative or analogues of
  • Keratinocyte KGF2 including amino acid substitutions , Stephen Ruben growth factor-2 allelic variations, deletions in sequence, et al deletion mutants fusion to molecules that increase half- - useful to life, amino acid additions to assist in
  • EP0815115B1 Keratinocyte KGF-2 sequences are amino acids 36 -172 and growth factor-2 1-172 (amino acids 1-36 are the signal
  • KGF-2 or amino acids; KGF-2 C terminal deletion Human Genome fibroblast mutants deleting at least one and up to 55 Science growth factor- amino acids where the N-terminal amino acid 12, FGF-12) residue of said KGF-2 C-terminal deletion
  • mutant is amino acid residue 1 (Met) , 36
  • EP1247530A2 Derwent Title (Thr), or 37 (Cys); N and C terminal
  • keratinocyte terminal deletion mutants include: Ala Human Genome growth factor (39)—Ser (208) (SEQ ID NO:l 16); Pro (47)- Science useful for -Ser (208) of FIG. 1 (SEQ ID NO:2); Val promoting and (77)—Ser (208) (SEQ ID NO:70); Glu (93) —
  • US6693077 contiguous amino deletion mutants include: Met (1), Thr acids from a (36), or Cys (37)—Lys (153 specific amino acid sequence Included are deletion mutants of' both N and C terminals as well as substituted amino acids
  • WO0170255A2 Combined KGF-1 or KGF-2 or analogs having at least treatment with partial human activity
  • keratinocyte Pfizer and OSI growth factor Pharmaceuticals and epidermal growth factor inhibitor WO0149309A2 Composition for KGF or KGF-2 or active variants, the treatment of homologues, derivatives or fragments
  • arg is linked to about 140 amino acids of USA Dept of the C-terminal core of ⁇ FGF (beginning at Health and residue 39, arg, and continuing to the C- Human Services terminal end of the ⁇ FGF coding sequence.
  • US5731170 includes KGF-like peptides with
  • EP0555205B1 DNA encoding a Sequences and potential variants of KGF in growth factor the claims including full length kgf,
  • WO02094872A1 Therapeutic uses KGF-2 amino acids 40-208 of keratinocyte
  • KGF-2A Novel KGF-2analog
  • Ni, Yawei et al enzyme least a 2-fold increase in mitogenic activity as compared to a mature full-
  • growth factor US20030147876A1 related to epithelial cell function and an extracellular matrix degrading enzyme is useful to treat injury of skin, oral cavity, digestive track, mucosal surface, eye or lung
  • WO0072872A1 Keratinocyte Preferred embodiments include the N- growth factor-2 terminal deletions Ala (63) — Ser (208)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)

Abstract

De manière générale, la présente invention a trait à des compositions, des conjugués, et des procédés comportant un agoniste de facteur de croissance de kératinocytes et un composé de gastrine. Les compositions peuvent être utilisées dans le traitement et/ou la prévention de conditions pour lesquelles soit un agoniste de facteur de croissance de kératinocytes ou un composé de gastrine ont révélé un effet thérapeutique, comprenant, mais de manière non exclusive, le diabète, l'hypertension, l'insuffisance cardiaque chronique, des états de rétention de fluides, le syndrome métabolique et des maladies et troubles associés, et l'obésité.
EP04730429A 2003-04-30 2004-04-30 Utilisation combinee d'agonistes de facteur de croissance de keratinocytes et de composes de gastrine Withdrawn EP1620464A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50906803P 2003-04-30 2003-04-30
PCT/CA2004/000648 WO2004096853A1 (fr) 2003-04-30 2004-04-30 Utilisation combinee d'agonistes de facteur de croissance de keratinocytes et de composes de gastrine

Publications (1)

Publication Number Publication Date
EP1620464A1 true EP1620464A1 (fr) 2006-02-01

Family

ID=33418513

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04730429A Withdrawn EP1620464A1 (fr) 2003-04-30 2004-04-30 Utilisation combinee d'agonistes de facteur de croissance de keratinocytes et de composes de gastrine

Country Status (5)

Country Link
EP (1) EP1620464A1 (fr)
JP (1) JP2007523840A (fr)
AU (1) AU2004233911A1 (fr)
CA (1) CA2522895A1 (fr)
WO (1) WO2004096853A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1837031B1 (fr) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methodes et compositions pour le traitement du diabete
DE60329724D1 (de) 2002-06-07 2009-11-26 Waratah Pharmaceuticals Inc Methoden und Kompositionen um Diabetes zu behandeln
RU2006131046A (ru) * 2004-01-30 2008-03-10 Уэрейта Фармасьютикалз, Инк. (Ca) Совместное применение агониста glp-1 и соединений гастрина
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
MX2009011898A (es) * 2007-05-04 2009-11-18 Ironwood Pharmaceuticals Inc Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido.
WO2009046873A1 (fr) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Utilisation combinée de vasonatrine et de gastrine-i en tant qu'agent thérapeutique
US11419916B2 (en) 2012-09-11 2022-08-23 Energesis Pharmaceuticals, Inc. Methods and compositions for inducing differentiation of human brown adipocyte progenitors
EP3110946B1 (fr) * 2014-02-24 2021-09-01 Energesis Pharmaceuticals Inc. Procédés et compositions destinés à induire la différentiation de progéniteurs des adipocytes bruns humains
US20220235106A1 (en) * 2019-04-05 2022-07-28 Korea Institute Of Ceramic Engineering And Technology Method for expressing and purifying protein by using csq-tag

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US5858977A (en) 1994-10-13 1999-01-12 Amgen Inc. Method of treating diabetes mellitus using KGF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004096853A1 *

Also Published As

Publication number Publication date
CA2522895A1 (fr) 2004-11-11
AU2004233911A1 (en) 2004-11-11
WO2004096853A1 (fr) 2004-11-11
JP2007523840A (ja) 2007-08-23

Similar Documents

Publication Publication Date Title
US11535659B2 (en) Engineered polypeptides having enhanced duration of action
EP3292141B1 (fr) Protéines de fusion
JP5937963B2 (ja) 新規Ｅｘｅｎｄｉｎ変異体及びその複合物
KR102365582B1 (ko) 인슐린 저항성에 대한 개선된 펩티드 약제
US8557769B2 (en) Co-administration of FGF-21 and GLP-1 to treat diabetes and lower blood glucose
US20040259780A1 (en) Method for treating diabetes and obesity
AU2008257448B2 (en) Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
TW202140065A (zh) 包含長效胰島素類似物接合物及長效促胰島素肽接合物之治療糖尿病組成物
EP1711532A2 (fr) Utilisation d'un agoniste de glp-1 associe a des composes gastriniques
EP1727559A1 (fr) Utilisation de fgf-21 et d'une thiazolidinedione pour traiter le diabete de type 2
JP2006520818A5 (fr)
CZ98197A3 (cs) Použití KGF nebo jeho analogu pro přípravu léčiva pro léčení cukrovky
KR20200078413A (ko) 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물
EP1620464A1 (fr) Utilisation combinee d'agonistes de facteur de croissance de keratinocytes et de composes de gastrine
EP3125921B1 (fr) Variants de fgf21 pour l'utilisation dans le traitement de la lipodystrophie partielle indue par arv/sida
US20090156494A1 (en) Compositions and methods comprising gastrin compounds
KR101417934B1 (ko) 비펩타이드성 중합체-인슐린 다량체 및 이의 제조방법
CN112279920B (zh) FGF21 Fc融合蛋白、GLP-1 Fc融合蛋白及它们的组合治疗剂和用途
CA2527186A1 (fr) Methodes et compositions contenant des composes de gastrine
US20040127412A1 (en) Modified GLP-1 peptides with increased biological potency
RU2804335C2 (ru) Слитый белок fgf21 fc, слитый белок glp-1 fc и комбинированный терапевтический агент, включающий их, и их применение
KR20060017617A (ko) 가스트린 화합물을 포함하는 조성물 및 이의 용도

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20061009

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070420